Search Results
25 Results Found for “glucagon-like peptide-1 receptor agonists (GLP-1 RAs)”
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
Fatty liver is the largest liver disease globally and has become a leading cause of liver cirrhosis and end-stage liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), affects about one-third of the adult population ...
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
In this Future Leader Q&A, Dr Sourabh Sharma, nephrologist and transplant physician, discusses the transformative role of mentorship, advances in transplantation and diabetic kidney disease, and his vision for equitable, patient-centred renal care.
Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...
The incidence of youth-onset type 2 diabetes (T2D) is increasing.1,2 Growing evidence has demonstrated that youth-onset T2D is rapidly progressive, with earlier onset of life-limiting complications compared with adult-onset T2D.3,4Â Initiation of effective treatment that can restore beta ...
Type 2 diabetes (T2DM) is a disease with a complex aetiopathogenesis that leads to a wide variety of metabolic disorders. This includes, by definition, high plasma glucose levels, but also elevated blood pressure, dyslipidaemia, cardiorenal complications and strokes. All of ...
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide.1,2Â For this reason, early diagnosis and treatment are relevant to prevent the progression of this disease. Currently, the urinary albumin excretion ...
Obesity – a chronic, relapsing, progressive disease that is defined by a body mass index (BMI) of ≥27.5 kg/m2 in Asian populations and ≥30.0 kg/m2 in all other populations – is an epidemic that has spread across the world.1 Recent data from ...
Chronic kidney disease (CKD) represents one of the greatest future public health challenges due, among other consequences, to its elevated burden on economic and human resources within healthcare systems.1Â Moreover, the rapid growth of type 2 diabetes mellitus (T2DM) results ...
The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly to become a global health threat. The disease is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel β-coronavirus that belongs to a family of enveloped RNA viruses, the coronaviruses.1 While ...
Pituitary adenomas are benign tumours that arise from the adenohypophysis. They are the second most frequent intracranial tumour type after meningiomas, and account for 16.2% of all primary cranial neoplasms.1 Though likely an underestimate, the incidence of pituitary adenomas is approximately ...
The glomeruli (also known as Malpighian bodies) were first described four and a half centuries ago, in 1666. Marcello Malpighi showed that these structures were a continuation of the renal vasculature. Two centuries later, in 1842, William Bowman detailed their architecture and ...
It hardly seems possible that only 21 years ago, the most exciting concept in type 2 diabetes (T2D) was the contribution of peripheral insulin resistance to disease pathophysiology, and the most important new tool to address this defect was the biguanide, ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced for the therapy of type 2 diabetes about 10 years ago, with exenatide the first drug in the class. Natural GLP-1 is secreted post-prandially by the L-cells of the intestine. It stimulates insulin secretion ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
